We are driven by a single mission: help bring safe solutions to unmet medical needs to patients faster—by improving the efficiency and integrity of the systems that power medical innovation.

Our leadership understands the realities of both patients and providers. We believe combining operational excellence with rigorous compliance strengthens data integrity, reduces complexity, and minimizes avoidable delays in the development of potentially life-saving therapies.

We translate urgency into compliant execution and patient-centered outcomes—enabling fewer audit findings, faster cycle times, and a lower total cost of compliance for sponsors. The result is larger, longer-duration engagements, higher renewal quality, and more predictable cash flow.

We build ecosystems of mission-critical service providers in the fragmented lower-middle market of the life sciences industry—bringing together businesses that accelerate each other’s ability to grow.

We combine digital platforms, consulting, and validation expertise to address the rising complexity and strategic importance of integrated regulatory, quality, and sustainability compliance.

We turn a single-service foothold into a lifecycle relationship—regulatory → validation → eQMS → pharmacovigilance → ESG/EHS → clinical compliance—delivered through one master services agreement (MSA) and one program management office (PMO). Sponsors reward simplicity and performance with larger scopes and longer contracts.

Durable, predictable cash flows

We acquire service provider businesses with recurring revenue characteristics, multi-year contracts, and high customer stickiness—supporting resilient cash flow and strong net revenue retention.

Proven roll-up mechanics with SPV protection

Our structure isolates risk, tailors financing by asset, and preserves exit optionality. Centralized governance, independent oversight, and KPI transparency provide investors defensible visibility while supporting margin expansion through operational improvements.

Life-sciences-native differentiation

SustainEnvi unifies ESG/EHS signals with quality, regulatory, pharmacovigilance, and site-network KPIs—creating a single audit-ready source of truth for sponsors.

Operational excellence and audit-first culture

Centralized QA/eQMS, validated data pipelines, and disciplined governance reduce audit burden, accelerate cycle times, and lower the total cost of compliance for sponsors—while improving reporting quality and working-capital predictability for investors.

Cross-marketing and scale

One MSA and a unified PMO enable bundled statements of work across the portfolio (Reg/Quality + Validation + SustainEnvi + Sites), increasing wallet share, raising retention, and compounding cash flow.

Aligned purpose and advantaged sourcing

A patient-first origin and community-embedded clinical trial sites attract talent and partners, strengthen sponsor relationships, and support proprietary opportunities—translating mission into measurable performance.

No major global player currently combines a buy-and-build, bolt-on aggregator strategy with a lower-middle-market focus and DSPVG/SustainEnvi’s level of operational and data integration. That “platform gap” is where we differentiate—and where we create value.

DSPVG HOLDINGS embeds ESG and sustainability principles into the operating DNA of every company we acquire. We view credible ESG and EHS practices as material risk controls and commercial differentiators.

We support sponsor expectations and EHS requirements through digital reporting, Scope-3 programs, and supplier risk management. Our leadership anchors academic partnerships, evidence-based rigor, and workforce development initiatives.

Our global access supports international partnerships that expand patient access and diversity—important for sponsor RFP competitiveness and post-market evidence strategies.